CA2870005A1 — Salt form of a human histone methyltransf erase ezh2 inhibitor
Assigned to Eisai R&D Management Co Ltd · Expires 2013-10-17 · 13y expired
What this patent protects
Abstract Provided herein is N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound. The compou…
USPTO Abstract
Abstract Provided herein is N-((4,6-dimethy1-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound. The compound described above and the Polymorph, or a pharmaceutical composition comprising either of these compounds, may be used to treat a variety of cancers, including non-Hodgkin's lymphoma or breast cancer. Date Recue/Date Received 2020-09-17
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.